Windtree Therapeutics Inc.’s recently made public that its President and CEO Fraser Craig acquired Company’s shares for reported $950.0 on Jul 27. In the deal valued at $0.38 per share,2,500 shares were bought. As a result of this transaction, Fraser Craig now holds 226,558 shares worth roughly $ 36249.28.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Hamill John P. bought 3,000 shares, generating $1,100 in total proceeds. Upon buying the shares at $0.37, the SVP & CFO now owns 72,800 shares.
Before that, Fraser Craig bought 2,500 shares. Windtree Therapeutics Inc. shares valued at $935 were divested by the President and CEO at a price of $0.37 per share. As a result of the transaction, Fraser Craig now holds 224,058 shares, worth roughly $35849.28.
Ladenburg Thalmann initiated its Windtree Therapeutics Inc. [WINT] rating to a Buy in a research note published on Friday, June 26, 2020; the price target was $12.25. PT values the company’s stock at a premium of 98.69 to its Friday closing price.
Price Performance Review of WINT
On Friday, Windtree Therapeutics Inc. [NASDAQ:WINT] saw its stock fall -8.83% to $0.16. On the same session, the stock had its day’s lowest price of $0.1519, but rose to a high of $0.172. Over the last five days, the stock has lost -11.67%. Windtree Therapeutics Inc. shares have fallen nearly -90.09% since the year began. Nevertheless, the stocks have fallen -91.26% over the past one year. While a 52-week high of $1.87 was reached on 01/03/22, a 52-week low of $0.15 was recorded on 11/03/22. SMA at 50 days reached $0.2991, while 200 days put it at $0.6265. A total of 0.65 million shares were traded, compared to the trading of 0.55 million shares in the previous session.
Levels Of Support And Resistance For WINT Stock
The 24-hour chart illustrates a support level at 0.1499, which if violated will result in even more drops to 0.1409. On the upside, there is a resistance level at 0.1700. A further resistance level may holdings at 0.1811. The Relative Strength Index (RSI) on the 14-day chart is 24.37, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0323, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.49%. Stochastics %K at 9.93% indicates the stock is a buying.
How much short interest is there in Windtree Therapeutics Inc.?
A steep rise in short interest was recorded in Windtree Therapeutics Inc. stocks on Jul 14, 2022, growing by 91760.0 shares to a total of 0.95 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 0.86 million shares. There was a rise of 9.65%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 4.37% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.81.
Windtree Therapeutics Inc. [WINT] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 577,946 shares, or roughly 1.89% of the outstanding WINT shares. In other words, the investor’s shares have risen by 32,579 from its previous 13-F filing of 545367.0. Additionally, Renaissance Technologies LLC increased 54.15% of its stake after which the total value it holdings stand at $108,419. At present, Millennium Management LLC is holding 79,858 shares valued at $23957.0. Northern Trust Investments, Inc. owned 50,176 shares of the company at the time of its most recent 13F filing, worth $15053.0.
According to FactSet, Windtree Therapeutics Inc.’s share price will average $3.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1664.71 percent from its previous closing price of $0.17. Analysts expect Windtree Therapeutics Inc. stock to reach the higher price of $3.00, while the lowest price estimate is $3.00. However, 2 analysts have rated WINT stock as a Buy in their predictions for 2022.